Lil­ly pays $10M up­front for Organo­vo’s FXR ag­o­nist pro­gram

Eli Lil­ly is buy­ing Organo­vo’s far­ne­soid X re­cep­tor (FXR) ag­o­nist pro­gram, which in­cludes a drug in Phase 2 de­vel­op­ment for ul­cer­a­tive col­i­tis and meta­bol­ic dys­func­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER